Genomize
Genomize turns genomic data into actionable insight with its AI-driven SEQ platform.
See it in action
Genomize SEQ: clinical variant interpretation and reporting. Video courtesy of Genomize.
More than a supplier. A local partner.
Local support
Field application and engineering teams across six cities in India, Gurugram, Delhi, Mumbai, Chennai, Bengaluru and Hyderabad, with defined response commitments.
Consumables continuity
Managed import, registration and cold-chain logistics keep reagents flowing without interruption.
Validated onboarding
In-house bioinformatics validate the platform into working pipelines, so it delivers results, not just readouts.
Flexible commercials
Payment flexibility, credit facilities for new accounts and co-investment in lab set-up.
The platform
SEQ delivers advanced NGS analysis with customisable variant interpretation, clinical and somatic reporting, and a Pathogenicity Calculator.
Where it fits
The interpretation and reporting stage of clinical and research NGS, with real-time genotype/phenotype database management.
Why we offer it
It turns variant lists into clear, defensible reports faster.
Where it sits in the Genique stack
Genomize SEQ is an interpretation and reporting layer. It is the step between a variant call file and something a clinician can read.
- What feeds it: secondary analysis from Sentieon or from Genique bioinformatics, on data from any supported sequencer.
- What it produces: customisable variant interpretation, clinical and somatic reporting, and a pathogenicity calculator, with real-time genotype and phenotype database management behind it.
- Where it fits: a lab that is content with the secondary analysis it already runs and wants the interpretation and reporting step on top, rather than one replacing the whole path.
- What Genique does with it: pipeline integration, so interpretation is a step in an existing workflow rather than a separate login.
How Genique supports it in India
A bioinformatics platform, so what a laboratory is planning for is a licence and an analysis budget rather than a delivery and an installation.
- Licensing: completed in under a week. There is no instrument to ship, so there is no installation window to plan around.
- Service: handled remotely, by the field application and engineering team in India.
- Training: for as many people as the laboratory needs trained rather than a fixed number of seats. Two to three hours.
- Analysis tokens: consumed per run and available immediately, so throughput is never waiting on a delivery.
Regulatory status in India
Genomize supplies variant interpretation and reporting software, labelled by the manufacturer for research use.
- Labelling: Research Use Only. That holds even where a product carries CE-IVD, CE-IVDR or FDA marking in another jurisdiction, because an approval granted elsewhere does not travel to India.
- CDSCO: nothing on this page is approved or licensed by the Central Drugs Standard Control Organisation as an in-vitro diagnostic device.
- What accreditation does and does not cover: accreditation of a laboratory evidences the quality system and the method validation under which work is performed. It does not change the regulatory status of an assay.
- What this means for a NABL laboratory: the software produces a draft that a laboratory reviews and signs out, and signing it out is the step that carries the clinical responsibility.
Resources
Brochures
Product and solution documentation, straight from Genomize.
Interested in Genomize?
Talk to our team about how it fits your needs.